Interferon-α induced thyroid dysfunction: Three clinical presentations and a review of the literature

Thyroid

Volumn 7, Issue 6, 1997, Pages 891-896

  Koh, Leonard K H ^a   Greenspan, Francis S ^b   Yeo, Peter P B ^b,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; FEMALE; HASHIMOTO DISEASE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; RISK FACTOR; THYROID DISEASE; THYROTOXICOSIS;

EID: 0031465313     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.1997.7.891     Document Type: Article

References (42)

1. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ, Hughes TK 1991 The interferons. Mechanisms of action and clinical applications. JAMA 266:1375-1383.
2. Vial T, Descotes J 1994 Clinical toxicity of the interfersons. Drug Safety 10:115-150.
3. Mayet WJ, Hess G, Gerken G, Rossol S, Voth R, Manns M, Meyer zum Buschenfelde KH 1989 Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10:24-28.
4. Saracco G, Touscoz A, Durazzo M, Rosina F, Donegani E, Chiandussi L, Gallo V, Petrino R, De Micheli AG, Solinas A, Deplano A, Tocco A, Cossu PA, Pintus C, Verme G, Rizzetto M 1990 Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis. J Hepatol 11: 339-343.
5. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N 1994 The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 89:399-403.
6. Imagawa A, Itoh N, Hanafusa T, Oda Y, Waguri M, Miyagawa J, Kono N, Kuwajima M, Matsuzawa Y 1995 Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 80:922-926.
7. Gillies M, Sarks J, Beaumont P, Hunyor A, McKay D, Kearns M, McClusky P, Sarks S 1993 Treatment of choroidal neovascularisation in age-related macular degeneration with interferon alfa-2a and alfa-2b. Br J Ophthalmol 77:766-770.
8. Vial T, Descotes J 1995 Immune-mediated side-effects of cytokines in humans. Toxicology 105:31-57.
9. Burman P, Totterman TH, Oberg K, Karlsson FA 1986 Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 63:1086-1090.
10. Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, Linkesch W, Weissel M 1992 Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 90:363-367.
11. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH 1992 Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 102:2155-2160.
12. Fonseca V, Thomas M, Dusheiko G 1991 Thyrotropin receptor antibodies following treatment with recombinant alpha-interferon in patients with hepatitis. Acta Endocrinol (Copenh) 125:491-493.
13. Waguri M, Hanafusa T, Itoh N, Imagawa A, Miyagawa J, Kawata S, Kono N, Kuwajima M, Matsuzawa Y 1994 Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res Clin Pract 23:33-36.
14. Ronnblom LE, Alm GV, Oberg KE 1991 Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115:178-183.
15. Conlon KG, Urba WJ, Smith JWd, Steis RG, Longo DL, Clark JW 1990 Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65:2237-2242.
16. Jacobs EL, Clare-Salzler MJ, Chopra IJ, Figlin RA 1991 Thyroid function abnormalities associated with the chronic out-patient administration of recombinant interleukin-2 and recombinant interferon-alpha. J Immunother 10:448-455.
17. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno E, Meroni PL, Colombo M, Beck-Peccoz P 1995 Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 132:587-593.
18. Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL 1985 Primary hypothyroidism associated with interferon therapy of breast cancer [letter]. Lancet 1:1166.
19. Berris B, Feinman SV 1991 Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis. Dig Dis Sci 36:1657-1660.
20. Pateron D, Hartmann DJ, Duclos-Vallee JC, Jouanolle H, Beaugrand M 1993 Latent autoimmune thyroid disease in patients with chronic HCV hepatitis [letter]. J Hepatol 17:417-419.
21. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, Regnier D, Dreyfus G, Pradier C, Sadoul JL, Hebuterne X, Rampal P 1993 High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy [see comments]. Hepatology 18:253-257.
22. Quaranta JF, Tran A, Regnier D, Letestu R, Beusnel C, Fuzibet JG, Thiers V, Rampal P 1993 High prevalence of anti-bodies to hepatitis C virus (HCV) in patients with anti-thyroid autoantibodies [letter]. J Hepatol 18:136-138.
23. Moskowitz C, Dutcher J, Wiernik P 1992 Association of thyroid disease with acute leukemia. Am J Hematol 39:102-107.
24. Baudin E, Marcellin P, Pouteau M, Colas-Linhart N, Le Floch JP, Lemmonier C, Benhamou JP, Bok B 1993 Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol (Oxf) 39:657-661.
25. Carella C, Amato G, Biondi B, Rotondi M, Morisco F, Tuccillo C, Chiuchiolo N, Signoriello G, Caporaso N, Lombardi G 1995 Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res 44:110-114.
26. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM 1988 Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318:1557-1563.
27. Reid I, Sharpe I, McDevitt J, Maxwell W, Emmons R, Tanner WA, Monson JR 1991 Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha. Br J Cancer 64:915-918.
28. Barreca T, Picciotto A, Franceschini R, Varagona G, Corsini G, Valle F, Cataldi A, Molinari E, Garibaldi A, Rolandi E 1993 Long term therapy with recombinant interferon alpha 2 b in patients with chronic hepatitis C: effects on thyroid function and autoantibodies. J Biol Regul Homeost Agents 7:58-62.
29. Primo J, Hinojosu J, Moles JR, Fernandez J, Martinez C, Miralles A, Orte A 1993 Development of thyroid dysfunction after alpha-interferon treatment of chronic hepatitis C [letter; comment]. Am J Gastroenterol 88:1976-1977.
30. Silvestri F, Virgolini L, Mazzolini A, Bertolissi F, Russo D, Fanin R, Baccarani M 1994 Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons. Haematologica 79:367-370.
31. Nagayama Y, Ohta K, Tsuruta M, Takeshita A, Kimura H, Hamasaki K, Ashizawa K, Nakata K, Yokoyama N, Nagataki S 1994 Exacerbation of thyroid autoimmunity by Interferon alpha treatment in patients with chronic viral hepatitis: Our studies and review of the literature. Endocr J 41:565-572.
32. Matsuda J, Saitoh N, Gotoh M, Gohchi K, Tsukamoto M, Syoji S, Miyake K, Yamanaka M 1995 High prevalence of anti-phospholipid antibodies and ami-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol 90:1138-1141.
33. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, Salvi M, Fiaccadori F, Ugolotti G, Neri T, Braverman L 1996 Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 172:482-487.
34. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, Garcia-Monzon C, Arranz A, Borque MJ, Moreno-Otero R 1996 Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 44:635-642.
35. Fattovich G, Betterle C, Brollo L, Pedini B, Giustina G, Realdi G, Alberti A, Ruol A 1991 Autoantibodies during alpha-interferon therapy for chronic hepatitis B. J Med Virol 34:132-135.
36. Reichen J, Bianchi L, Frei PC, Male PJ, Lavanchy D, Schmid M 1994 Efficacy of steroid withdrawal and low-dose interferon treatment in chronic active hepatitis B. Results of a randomized multicenter trial. Swiss Association for the Study of the Liver. J Hepatol 20:168-174.
37. Vallisa D, Cavanna L, Berte R, Merli F, Ghisoni F, Buscarini L 1995 Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. Acta Haematol 93:31-35.
38. Fentiman IS, Balkwill FR, Thomas BS, Russell MJ, Todd I, Bottazzo GF 1988 An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 24:1299-1303.
39. Schultz M, Muller R, von zur Muhlen A, Brabant G 1989 Induction of hyperthyroidism by interferon-alpha-2b [letter]. Lancet 1:1452.
40. Kalkner M, Hagberg H, Karlsson-Parra A 1990 Autoantibody occurrence in hairy-cell leukemia during prolonged interferon treatment [letter]. Eur J Haematol 45:233-234.
41. Graus J, Barcena R, Urena V, Caballero C, Lancha C, Chi T 1993 Thyroid disease during therapy of chronic hepatitis C with IFN treatment. J Hepatol 18(Suppl 1):126.
42. Chung YH, Shong YK 1993 Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis. Am J Gastroenterol 88:244-247.